title: Prognostic significance of microRNA-16 expression in human colorectal cancer.
abstract: BACKGROUND
  MicroRNAs (miRNAs), small noncoding RNAs, have been reported to be highly involved in the formation and progression of all types of human cancer including colorectal cancer (CRC). Therefore, miRNAs are also potential prognostic biomarkers in CRC patients. The aim of this study was to detect the expression of miR-16 in human CRC tissues and investigate its clinicopathologic or prognostic significance.
  
  
  METHODS
  TaqMan quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay was performed to determine the expression of miR-16 in 143 primary CRC tissues and 18 corresponding normal colonic mucosa from patients who had undergone surgery. The association of miR-16 expression with clinicopathologic features of CRC patients was statistically analyzed. Kaplan-Meier analyses were used to assess patient survival. Univariate and multivariate Cox analyses were performed.
  
  
  RESULTS
  The relative level of miR-16 in 18 CRC tissues was significantly lower than that in corresponding normal colonic mucosa (p < 0.001). Statistical analyses revealed that the status of miR-16 expression was closely associated with tumor differentiation, lymph node metastasis, L category, V category, TNM stage, and tumor recurrence of CRC (p = 0.001, 0.003, 0.001, 0.005, 0.003, and 0.017, respectively). Kaplan-Meier analyses indicated that patients with low-miR-16 had lower 5-year overall survival than those with high-miR-16 (31.2 vs. 58.3 %; p = 0.0012). Multivariate Cox regression analyses indicated that the status of miR-16 expression might be an independent prognostic factor for CRC patients (hazard ratio 1.67; 95 % confidence interval 1.22-2.54; p = 0.018).
  
  
  CONCLUSIONS
  Down-regulation of miR-16 plays critical roles in CRC progression. Low miR-16 expression is an independent factor predicting a poor prognosis for CRC patients.
authors.affiliation: Department of Oncology, The Third Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, No. 1 Jinling Road, Nanjing, Jiangsu, 210029, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Qian
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Juan
authors.initials: J
authors.lastname: Chen
authors.forename: Mingzhi
authors.initials: M
authors.lastname: Fang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015331:Cohort Studies; D003106:Colon / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D011379:Prognosis; D012372:ROC Curve; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C505362:MIRN16 microRNA, human; D035683:MicroRNAs
references.citation: Mol Oncol. 2012 Dec;6(6):590-610
references.pmid: 23102669
references.citation: Cancer Lett. 2013 Feb 1;329(1):84-90
references.pmid: 23111103
references.citation: Curr Opin Oncol. 2012 Nov;24(6):655-9
references.pmid: 23079782
references.citation: Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):331-45
references.pmid: 11969242
references.citation: Leuk Res. 2012 Dec;36(12):1505-9
references.pmid: 22959509
references.citation: Cancer Lett. 2013 Feb 28;329(2):125-36
references.pmid: 23196059
references.citation: CA Cancer J Clin. 2009 Nov-Dec;59(6):366-78
references.pmid: 19897840
references.citation: Mol Ther. 2010 Jan;18(1):181-7
references.pmid: 19738602
references.citation: PLoS One. 2012;7(11):e50935
references.pmid: 23226427
references.citation: Dig Liver Dis. 2012 Mar;44(3):195-200
references.pmid: 22105087
references.citation: J Surg Oncol. 2011 Apr;103(5):411-5
references.pmid: 21400525
references.citation: Chirurgia (Bucur). 2012 Sep-Oct;107(5):555-63
references.pmid: 23116828
references.citation: Anticancer Res. 2004 Jul-Aug;24(4):2519-30
references.pmid: 15330208
references.citation: PLoS One. 2012;7(9):e44398
references.pmid: 22970209
references.citation: Hum Pathol. 2013 Jun;44(6):1011-6
references.pmid: 23260326
references.citation: Oncol Rep. 2012 Dec;28(6):2221-6
references.pmid: 23023298
references.citation: RNA Biol. 2012 Jun;9(6):850-9
references.pmid: 22699556
references.citation: IUBMB Life. 2011 Feb;63(2):101-8
references.pmid: 21360639
references.citation: Eur J Cancer. 2005 Aug;41(12):1690-6
references.pmid: 16043346
references.citation: Oncol Rep. 2013 Apr;29(4):1652-8
references.pmid: 23380758
references.citation: Cancer J. 2012 May-Jun;18(3):244-52
references.pmid: 22647361
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Expert Rev Anticancer Ther. 2012 Feb;12(2):283-8
references.pmid: 22316375
references.citation: Br J Cancer. 2012 May 22;106(11):1826-32
references.pmid: 22549179
references.citation: Curr Opin Chem Biol. 2003 Aug;7(4):516-23
references.pmid: 12941428